ArticleInternational immunopharmacology2021
Serum Amyloid A Protein as a useful biomarker to predict COVID-19 patients severity and prognosis.
Article in International immunopharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 39 citations in OpenAlex.
- The Ability of Serum Amyloid A to Discriminate Coronavirus Disease 2019 (COVID-19) Patients Who Stay Moderately Ill Versus Patients Who Become Severely Ill.Journal of clinical laboratory analysis · 2026Article
- Intranasal SARS-CoV-2 infection changes the transcriptome of the mouse trigeminal ganglion and brainstem: potential mechanisms underlying headache and trigeminal pain presentation in COVID-19.Journal of neuroinflammation · 2026Article
- Longitudinal Analysis of Heparin-Binding Protein (HBP) and Serum Amyloid a Protein (SAA) Versus Interleukin 6 (IL-6), C-Reactive Protein (CRP), and Procalcitonin (PCT) During Both the Acute Postoperative Period and Recovery at Three Months From Non-emergent Cardiac Surgery.Clinical Medicine Insights. Cardiology · 2026Article
- Combined serum amyloid A and heparin-binding protein levels on admission reliably predict the severity and outcomes of COVID-19 infection in elderly patients: a retrospective study from Hangzhou, China.Annals of medicine · 2025Article
- VCL/ICAM-1 pathway is associated with lung inflammatory damage in SARS-CoV-2 Omicron infection.Nature communications · 2025Article
- Proteomic and metabolomic analysis of serum in women infected with COVID-19 during late pregnancy.Frontiers in immunology · 2025Article
- Longitudinal Analysis of Traditional Inflammatory Markers (IL-6, CRP) Juxtaposed With Heparin-Binding Protein (HBP) and Serum Amyloid A Protein Component (SAA) During Acute Infection and Convalescence From COVID-19 Infection in the Context of Initial Viral Load and Markers of Tissue Destruction.Journal of immunology research · 2025Article
- Effect of a SARS-CoV-2 Protein Fragment on the Amyloidogenic Propensity of Human Islet Amyloid Polypeptide.ACS chemical neuroscience · 2024Article
- IL-6 and SAA-Strong Predictors for the Outcome in COVID-19 CKD Patients.International journal of molecular sciences · 2023Article
- Post COVID-19 complications and follow up biomarkers.Nanoscale advances · 2023Review
- COVID-19 Infection and Vaccination and Its Relation to Amyloidosis: What Do We Know Currently?Vaccines · 2023Review
- Article
- Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy.Pharmaceutics · 2023Review
- Adherence to the Mediterranean Diet Association with Serum Inflammatory Factors Stress Oxidative and Appetite in COVID-19 Patients.Medicina (Kaunas, Lithuania) · 2023Article
- Inflammageing and Cardiovascular System: Focus on Cardiokines and Cardiac-Specific Biomarkers.International journal of molecular sciences · 2023Review
- Serum amyloid A-A potential therapeutic target for hyper-inflammatory syndrome associated with COVID-19.Frontiers in medicine · 2023Review
- Elevated Serum Amyloid A Levels Contribute to Increased Platelet Adhesion in COVID-19 Patients.International journal of molecular sciences · 2022Article
- Evaluation of Hepcidin Level in COVID-19 Patients Admitted to the Intensive Care Unit.Diagnostics (Basel, Switzerland) · 2022Article
- Article
- Role of Serum Amyloid A as a Biomarker for Predicting the Severity and Prognosis of COVID-19.Journal of immunology research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus Disease 2019 (COVID-19) can present with different grades of severity from mild to critical. Evaluation of biomarkers predicting severity is crucial to identify patients at high risk of disease progression and poor prognosis. Serum Amyloid A (SAA) is an acute-phase protein mainly produced by the liver in response to pro-inflammatory cytokines. In this study, we investigated SAA levels at admission (T1) and after 15 days (T2) of hospitalization in two groups of patients: survivors and non-survivors. At T1, the non-survivors showed higher SAA level than survivors (74 mg/dL vs 48.75 mg/dL). At T2, the survivor group value decreased to 6.55 mg/dL, the non-survivor group still showed high levels (51.1 mg/dL). The SAA level in control group was 0.35 mg/dL. Furthermore, a cut-off value of 63 mg/dL able to discriminate survivors from non-survivors was established by ROC curve analysis at T1. At T2, the cut-off decreased to 30.9 mg/dL. A similar decreasing trend was observed for D-Dimer, hsCRP, IL-6 and procalcitonin levels. The results of this retrospective study suggest that SAA is a good marker of COVID-19 disease alone and/or in combination with other inflammatory biomarkers. Identification of reliable prognostic analytes is of great clinical relevance, as it would improve patient management besides being costs saving.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.